MA32453B1 - Manoparticules inograniques, leur preparation et leurs utilisations - Google Patents

Manoparticules inograniques, leur preparation et leurs utilisations

Info

Publication number
MA32453B1
MA32453B1 MA33490A MA33490A MA32453B1 MA 32453 B1 MA32453 B1 MA 32453B1 MA 33490 A MA33490 A MA 33490A MA 33490 A MA33490 A MA 33490A MA 32453 B1 MA32453 B1 MA 32453B1
Authority
MA
Morocco
Prior art keywords
particles
relates
health
vivo
field
Prior art date
Application number
MA33490A
Other languages
Arabic (ar)
English (en)
Inventor
Laurent Levy
Agnès Pottier
Annabelle Rouet
Julie Marill
Corinne Devaux
Matthieu Germain
Original Assignee
Nanobiotix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobiotix filed Critical Nanobiotix
Publication of MA32453B1 publication Critical patent/MA32453B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Radiation-Therapy Devices (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne de nouvelles particules excitables pouvant être utilisées dans le domaine de la santé. Elle concerne plus particulièrement des particules pouvant générer des électrons et/ou un photon à haute énergie lorsqu'elles sont excitées par des rayonnements ionisants tels que le rayons x, les rayons gamma, un isotope radioactif et/ou des faisceaux électroniques. Elle concerne les utilisations de ces particules dans le domaine de la santé, notamment de la santé humaine. Les particules de l'invention sont constituées d'une matière inorganique contenant de l'oxygène, en particulier un oxyde, ladite matière présentant une densité appropriée et pouvant être activée in vitro, ex vivo ou in vivo par excitation externe réglable, en vue de perturber, de modifier ou de détruire des cellules cibles, des tissus ou des organes. L'invention concerne en outre des méthodes de production desdites particules, et des compositions pharmaceutiques ou pour dispositifs médicaux contenant ces particules.
MA33490A 2008-06-05 2011-01-04 Manoparticules inograniques, leur preparation et leurs utilisations MA32453B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08157686A EP2130553A1 (fr) 2008-06-05 2008-06-05 Nanoparticules inorganiques de haute densité pour détruire des cellules in-vivo
US6020208P 2008-06-10 2008-06-10
PCT/EP2009/056880 WO2009147214A2 (fr) 2008-06-05 2009-06-04 Nanoparticules inorganiques, leur préparation et leurs utilisations

Publications (1)

Publication Number Publication Date
MA32453B1 true MA32453B1 (fr) 2011-07-03

Family

ID=39734334

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33490A MA32453B1 (fr) 2008-06-05 2011-01-04 Manoparticules inograniques, leur preparation et leurs utilisations

Country Status (26)

Country Link
US (1) US8845507B2 (fr)
EP (4) EP2130553A1 (fr)
JP (1) JP5734181B2 (fr)
KR (1) KR101639281B1 (fr)
CN (1) CN102056628B (fr)
AU (1) AU2009254550B2 (fr)
BR (1) BRPI0913410B1 (fr)
CA (1) CA2727576C (fr)
CY (2) CY1118217T1 (fr)
DK (2) DK2300054T3 (fr)
EA (1) EA023012B1 (fr)
ES (2) ES2702249T3 (fr)
HR (2) HRP20161465T8 (fr)
HU (2) HUE040247T2 (fr)
IL (1) IL209625A (fr)
LT (2) LT3150227T (fr)
MA (1) MA32453B1 (fr)
MX (1) MX2010013322A (fr)
NZ (1) NZ589888A (fr)
PL (2) PL3150227T3 (fr)
PT (2) PT2300054T (fr)
SG (1) SG10201405288WA (fr)
SI (2) SI3150227T1 (fr)
TR (1) TR201819077T4 (fr)
WO (1) WO2009147214A2 (fr)
ZA (1) ZA201100082B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004075975A2 (fr) * 2003-02-24 2004-09-10 Pomper Mark E Vehicule de radiotherapie mobile et methode associee
US8459714B2 (en) 2006-05-19 2013-06-11 Breya, Llc. Mobile radiation therapy
US8657354B2 (en) 2006-05-19 2014-02-25 Breya, Llc. Mobile radiation therapy
US8728440B2 (en) 2012-08-23 2014-05-20 General Electric Company Nanoparticulate compositions for diagnostic imaging
US9399075B2 (en) 2008-12-29 2016-07-26 General Electric Company Nanoparticle contrast agents for diagnostic imaging
US9585840B1 (en) 2009-07-10 2017-03-07 University Of Central Florida Research Foundation, Inc. Redox active cerium oxide nanoparticles and associated methods
EP2275137A1 (fr) 2009-07-10 2011-01-19 Nanobiotix Nanoparticules métalliques, leur préparation et utilisations
CN102870235B (zh) 2009-11-10 2016-11-23 免疫之光有限责任公司 用于从包括用于上变频的射频、微波能量和磁感应源的各种能量源产生发射光的上下变频系统
WO2012058271A2 (fr) 2010-10-27 2012-05-03 Pixelligent Technologies, Llc Synthèse, coiffage et dispersion de nanocristaux
CN102947218B (zh) * 2010-04-23 2016-05-11 皮瑟莱根特科技有限责任公司 纳米晶体的合成、盖帽和分散
US9359689B2 (en) 2011-10-26 2016-06-07 Pixelligent Technologies, Llc Synthesis, capping and dispersion of nanocrystals
JP6042450B2 (ja) 2011-12-16 2016-12-14 ナノビオティックスＮａｎｏｂｉｏｔｉｘ 金属材料および酸化ハフニウム材料を含むナノ粒子、その製造および使用
US20150141875A1 (en) * 2012-06-14 2015-05-21 The Board Of Trustees Of The University Of Arkansas Compositions and methods for non-invasive detection and treatment of hypoxic cells in vivo
US8821838B2 (en) 2012-08-23 2014-09-02 General Electric Company Nanoparticulate compositions for diagnostic imaging
PL2948179T3 (pl) * 2013-01-25 2019-10-31 Nanobiotix Kompozycje zawierające nanocząstki tlenku hafnu(iv) lub tlenku renu(iv) w połączeniu z promieniowaniem jonizującym do leczenia nowotworu
JP6693868B2 (ja) * 2013-02-19 2020-05-13 ナショナル ヘルス リサーチ インスティテューツＮａｔｉｏｎａｌ Ｈｅａｌｔｈ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅｓ 抗癌化学療法剤用のケージ化された白金ナノクラスタ
MA38687A1 (fr) 2013-05-30 2017-12-29 Nanobiotix Composition pharmaceutique, préparation et utilisations de celle-ci
AU2014283217A1 (en) * 2013-06-20 2015-12-24 Nanobiotix Compositions and methods for use in medical diagnosis
BR112016012410A2 (pt) * 2013-12-16 2017-09-26 Genentech Inc conjugado de droga e anticorpo, composto conjugado de droga e anticorpo, composto não-peptídico, método de tratamento de doenças em seres humanos e composição farmacêutica
EP2886128A1 (fr) 2013-12-20 2015-06-24 Nanobiotix Compositions pharmaceutiques comportant des nanoparticules, leur préparation et leur utilisation
DK3223796T3 (da) 2014-11-25 2021-09-27 Curadigm Sas Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
AU2015352685B2 (en) 2014-11-25 2020-09-17 Nanobiotix Pharmaceutical composition, preparation and uses thereof
WO2016083336A1 (fr) 2014-11-25 2016-06-02 Nanobiotix Composition pharmaceutique, sa préparation et ses utilisations
PL3229843T3 (pl) 2014-11-25 2020-06-29 Curadigm Sas Kompozycja farmaceutyczna, wytwarzanie i zastosowanie tej kompozycji
PT3229776T (pt) 2014-11-25 2023-08-17 Curadigm Sas Composição farmacêutica combinando pelo menos duas nanopartícuas distintas e um composto farmacêutico, preparaçâo e suas utilizações
WO2016112268A1 (fr) * 2015-01-08 2016-07-14 Purdue Research Foundation Particules radioluminescentes pour l'amélioration de la radiothérapie du cancer
JP2018516256A (ja) * 2015-05-28 2018-06-21 ナノビオティックスＮａｎｏｂｉｏｔｉｘ 治療用ワクチンとしての使用のためのナノ粒子
US11389536B2 (en) 2015-07-17 2022-07-19 BioCurity Pharmaceuticals Inc. Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
CN109010828B (zh) * 2018-10-12 2020-10-20 中国科学院高能物理研究所 一种二硫化钼/二氧化铪的复合纳米材料、其制备方法及用途
CN109616308B (zh) * 2018-11-07 2020-09-04 湖北第二师范学院 一种球形纳米氧化铱dna提取磁性粉末及其生产方法
CN109771645B (zh) * 2019-03-07 2021-08-24 广西师范大学 一种二氧化钌复合卵清蛋白纳米材料的制备及其应用
EP4157457A1 (fr) * 2020-05-26 2023-04-05 Nanobiotix Nanoparticules, rayonnement ionisant et leurs combinaisons thérapeutiques innovantes
AU2021374754A1 (en) * 2020-11-05 2023-06-22 Nanobiotix Compositions of nanoparticles for treatment of cancer
EP4255488A1 (fr) * 2020-12-01 2023-10-11 Nanobiotix Particules poreuses, à haute teneur en z et exemptes de carbone en tant que radioactivateurs
CA3234824A1 (fr) * 2021-11-23 2023-06-01 Universitat Basel Nanoparticules d'oxyde d'hafnium (iv) et compositions aqueuses de celles-ci
AR131316A1 (es) 2022-12-12 2025-03-05 Nanobiotix S A Novedosas nanopartículas de óxido de metal y composiciones de las mismas para uso como radiopotenciadores o para visualizar tejido biológico
EP4595983A1 (fr) 2024-02-05 2025-08-06 BXTA Nanotherapy Limited Nanoparticules fonctionnalisées avec un agent stabilisant et un agent de ciblage
WO2026074471A1 (fr) * 2024-10-02 2026-04-09 Janssen Pharmaceutica Nv Polythérapies avec des nanoparticules d'oxyde d'hafnium et des anticorps pd-l1 destinés à être utilisés dans le traitement du cancer du poumon non à petites cellules

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6287526A (ja) * 1985-10-11 1987-04-22 Akira Fujishima 抗腫瘍剤
WO2000006244A2 (fr) 1998-07-30 2000-02-10 Hainfeld James F Particules metalliques de chargement dans des vesicules membranaires cellulaires et particule metallique utilisee pour l'imagerie et la therapie
EP1696957A2 (fr) 2003-12-17 2006-09-06 Philips Intellectual Property & Standards GmbH Radiotherapie et imagerie medicale au moyen de nanoparticules emettant des rayons ultraviolets
FR2869803B1 (fr) * 2004-05-10 2006-07-28 Nanobiotix Sarl Particules activables, preparation et utilisations
US20070092927A1 (en) * 2005-06-13 2007-04-26 University Of Dayton Photocatalytic particles with directed and controlled redox activity
JP2007075696A (ja) * 2005-09-13 2007-03-29 Mitsubishi Materials Corp 多孔質光触媒膜
RU2009104312A (ru) * 2006-07-10 2010-08-20 Конинклейке Филипс Электроникс Н.В. (Nl) Наночастицы типа "ядро-оболочка" для терапии и диагностических целей
EP1920784A1 (fr) * 2006-11-13 2008-05-14 Koninklijke Philips Electronics N.V. Sensibilisateurs de radiation pour la thérapie par rayonnements ionisants et pour l'imagerie

Also Published As

Publication number Publication date
LT3150227T (lt) 2018-12-10
PT2300054T (pt) 2016-11-11
SG10201405288WA (en) 2014-10-30
CY1118217T1 (el) 2017-06-28
BRPI0913410A2 (pt) 2015-11-24
WO2009147214A2 (fr) 2009-12-10
LT2300054T (lt) 2016-12-27
DK3150227T3 (en) 2019-01-14
PL3150227T3 (pl) 2019-05-31
TR201819077T4 (tr) 2019-01-21
CY1121078T1 (el) 2019-12-11
US8845507B2 (en) 2014-09-30
MX2010013322A (es) 2011-01-21
BRPI0913410B1 (pt) 2021-09-21
PT3150227T (pt) 2018-12-24
EA023012B1 (ru) 2016-04-29
AU2009254550A1 (en) 2009-12-10
HUE030669T2 (en) 2017-05-29
EP2300054A2 (fr) 2011-03-30
HRP20161465T8 (hr) 2017-04-21
SI2300054T1 (sl) 2017-02-28
HRP20181993T1 (hr) 2019-01-25
EP2130553A1 (fr) 2009-12-09
EP3150227B1 (fr) 2018-10-31
EP3461502A1 (fr) 2019-04-03
DK2300054T3 (en) 2016-12-05
IL209625A0 (en) 2011-02-28
ES2602048T3 (es) 2017-02-17
HRP20161465T1 (hr) 2017-01-27
AU2009254550B2 (en) 2013-10-24
CN102056628B (zh) 2013-07-10
KR101639281B1 (ko) 2016-07-13
EA201071429A1 (ru) 2011-06-30
EP3150227A1 (fr) 2017-04-05
JP2011524866A (ja) 2011-09-08
CA2727576A1 (fr) 2009-12-10
NZ589888A (en) 2012-06-29
CA2727576C (fr) 2016-08-16
KR20110028616A (ko) 2011-03-21
SI3150227T1 (sl) 2019-02-28
ZA201100082B (en) 2011-10-26
US20110213192A1 (en) 2011-09-01
JP5734181B2 (ja) 2015-06-17
WO2009147214A3 (fr) 2010-02-25
ES2702249T3 (es) 2019-02-28
CN102056628A (zh) 2011-05-11
HUE040247T2 (hu) 2019-02-28
IL209625A (en) 2015-11-30
PL2300054T3 (pl) 2017-04-28
EP2300054B1 (fr) 2016-09-07

Similar Documents

Publication Publication Date Title
CY1121078T1 (el) Ανοργανα νανοσωματιδια υψηλης πυκνοτητας για καταστροφη κυτταρων in-vivo
Capuano et al. Nanoparticles and their antibacterial application in endodontics
MA38318A1 (fr) Compositions de nanoparticules inorganiques combinées à des rayonnements ionisants pour le traitement du cancer
Eick et al. In vitro-activity of Er: YAG laser in comparison with other treatment modalities on biofilm ablation from implant and tooth surfaces
Mozayeni et al. Antimicrobial effects of four intracanal medicaments on enterococcus faecalis: an in vitro study
FR2869803A1 (fr) Particules activables, preparation et utilisations
Zand et al. Comparison of the penetration depth of conventional and nano-particle calcium hydroxide into dentinal tubules
Tennert et al. Ultrasonic activation and chemical modification of photosensitizers enhances the effects of photodynamic therapy against Enterococcus faecalis root-canal isolates
CO6311006A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+ efectiva a dosis altas
Maaoui et al. A 980 nm driven photothermal ablation of virulent and antibiotic resistant Gram-positive and Gram-negative bacteria strains using Prussian blue nanoparticles
CO6670567A2 (es) Métodos de tratamiento contra el cáncer pancreático
BR112012000530B8 (pt) uso de uma população de nanopartículas de ouro, e, composição farmacêutica
AR068185A1 (es) Composiciones de tabletas de desintegracion oral de lamotrigina
Diogo et al. Is the chlorophyll derivative Zn (II) e6Me a good photosensitizer to be used in root canal disinfection?
Ozen et al. Dosimetric evaluation of the effect of dental implants in head and neck radiotherapy
WO2008093869A1 (fr) Matière fluorescente, scintillateur utilisant la matière fluorescente et détecteur de rayonnement
PE20060002A1 (es) Combinaciones antineoplasicas de cci-779 y rituximab
Walsh Novel approaches to detect and treat biofilms within the root canals of teeth: A review
Gambarini et al. In vitro evaluation of the cytotoxicity of FotoSan™ light-activated disinfection on human fibroblasts
Liu et al. Near–infrared light–cured dental restoration materials with upconversion nanoparticles
Shirur et al. Development of lipidic nanoplatform for intra-oral delivery of chlorhexidine: characterization, biocompatibility, and assessment of depth of penetration in extracted human teeth
Dang et al. Ultrasound-activated nanodroplet disruption of the Enterococcus faecalis biofilm in dental root canal
Popova et al. Cerium oxide nanoparticles provide radioprotective effects upon X-ray irradiation by modulation of gene expression
López et al. Effect of different irrigating solutions and photo-activated therapy for in vivo root canal treatment
Dos Santos et al. Antimicrobial Properties of Graphene Applied in Endodontic Agents and Materials: A Scoping Review